pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN® for use ...
US-based specialty pharmaceutical company, pSivida has entered into a funded technology evaluation agreement with an undisclosed pharmaceutical company. The deal will assess the Durasert technology, pSivida's core technology system, for ...
pSivida has announced the availability of the sustained release pharmaceutical product indicated for the treatment of chronic diabetic macular edema (DME), Iluvien, in Germany. Alimera Sciences, pSivida's licensee, has reported the ...
Tags: pSivida Iluvien, Medicine
pSivida has completed enrolling first US patient in investigator-sponsored clinical trial of its injectable sustained release insert. pSivida president and CEO Ashton said the trial will study the use of injectable micro-inserts to treat ...
Tags: pSivida, clinical trial, injectable sustained release insert
The Federal Ministry of Health of Germany has granted marketing authorization to pSivida for injectable, sustained-release intravitreal insert, Iluvien, designed as a treatment for vision impairment associated with chronic diabetic macular ...
Tags: Psivida, DME, clinical product
pSivida, a developer of sustained release drug delivery products, has entered into an agreement with a biopharmaceutical company for the evaluation of its Tethadur protein/antibody delivery technology. Designed for use in the field of ...
The US Food and Drug Administration (FDA) has approved pSivida's investigational new drug (IND) application for injectable sustained-release micro-insert, designed as a treatment for posterior uveitis. pSivida's injectable ...
pSivida has signed a funded technology evaluation agreement with a biopharmaceutical company to evaluate pSivida's Tethadur protein/antibody delivery technology in the field of ophthalmology. Tethadur, which uses an injectable, ...
The National Security Agency of Medicines and Health Products in France has granted marketing authorization to pSivida's ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME). The injectable, ...
Ferrer Internacional has decided to withdraw the marketing authorisation application (MAA) for Egrifta (tesamorelin) 2mg, powder for solution for injection in Europe. Ferrer formally notified the European Medicines Agency of its decision. ...
Tags: DME, healthcare products, pSivida
UK-based Medicines and Healthcare products Regulatory Agency(MHRA)has granted marketing authorization to pSivida for its Iluvien insert. The marketing authorization follows the recently announced approval in Austria. The approvals were ...
Tags: pSivida Iluvien insert, MHRA, intravitreal insert, Iluvien
The Austrian Agency for Health and Food Safety has issued marketing authorization to pSivida ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME). The injectable, sustained-release ...
Tags: Marketing Authorization, reatment of vision impairment, clinical product